+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the effectiveness and quality of life outcomes of neoadjuvant endocrine therapy compared to chemotherapy in participants with early or locally advanced hormone receptor-positive, HER2-negative breast cancer who have no detectable circulating tumor DNA ctDNA in their blood. This study focuses on determining if endocrine therapy is at least equivalent to chemotherapy for those who respond to initial aromatase inhibitor treatment, using the modified preoperative endocrine prognostic index PEPI score as the main measure. Participants initially provide blood and tumor samples for ctDNA testing using the SignateraTM test. They then take aromatase inhibitor therapy for 4 weeks during a Run-in Phase, with a tumor biopsy after 3 weeks to assess Ki-67 levels. Based on ctDNA results and Ki-67 values, participants are assigned to one of three groups neoadjuvant aromatase inhibitor or tamoxifen treatment, neoadjuvant chemotherapy for endocrine responders, or chemotherapy for non-responders. Treatment lasts 6 to 8 months depending on the group. During the study, participants visit the clinic several times, including before starting treatment, after 3 weeks of endocrine therapy, before beginning the main treatment, mid-therapy, after treatment completion, for surgery and post-surgery checkups, and annually for 5 years after surgery. They provide blood samples for ongoing ctDNA assessment and complete questionnaires on quality of life, symptoms, and sexual health. The study tracks outcomes like PEPI score at surgery and long-term survival and disease-free survival over 5 years.

Age: 18Years - 100YearsAll GendersPhase Not Applicable
14 locations
A

Actively Recruiting

Researchers are investigating if, for patients with clinically node-positive breast cancer undergoing upfront surgery, treatment with tailored axillary surgery TAS combined with axillary radiotherapy ART is better than axillary lymph node dissection ALND in improving arm-related quality of life QoL and reducing lymphedema two years after treatment. ALND is currently the standard treatment but is associated with major side effects. TAS targets positive lymph nodes more selectively than ALND, potentially causing less harm when combined with ART. The study compares two treatment approaches one group undergoes ALND, the standard surgery removing all lymphatic tissue in the axilla, alongside breast irradiation excluding the axilla the other group receives TAS, which includes sentinel lymph node biopsy and targeted removal of suspicious nodes, combined with breast and axillary radiotherapy ART. All patients receive adjuvant breast irradiation following breast-conserving surgery, with or without axillary radiotherapy depending on their group. The trial follows participants from surgery through post-treatment monitoring. Participants will be assessed from baseline through two years after randomization to monitor changes in arm-related QoL and the occurrence of lymphedema. Researchers will collect quality of life questionnaires and clinical evaluations to measure these outcomes. The study includes randomization into treatment groups and involves regular follow-up to assess long-term effects on arm function and side effects. The overall goal is to determine if TAS plus ART offers improved quality of life compared to ALND.

Age: 18Years +All GendersPhase Not Applicable
55 locations
R

Actively Recruiting

Researchers are studying metastatic breast cancer, the most common cancer among women worldwide, with a focus on patients in Austria. This study is the first Austrian-wide registry to systematically collect and document data on metastatic breast cancer cases. The aim is to understand epidemiological trends and treatment patterns, including tumor characteristics and patient outcomes. The study collects both retrospective and prospective data from multiple centers across Austria. It records detailed information on tumor subtypes, initial disease progression, treatment sequences, and patient medical histories. This registry also includes data on male breast cancer patients to assess gender differences in treatment and outcomes. Participants provide anonymized medical information, including tumor characteristics, treatment details, and survival data. Researchers will analyze patterns of metastasis, treatment responses, and survival rates at 1, 2, and 5 years after metastasis diagnosis. The registry aims to offer insights into treatment quality and outcomes over a 10-year period.

Age: 18Years +All Genders
16 locations